GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 233 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $213,000 | -45.4% | 6,672 | -40.7% | 0.01% | -44.4% |
| Q1 2022 | $390,000 | -50.5% | 11,260 | -58.2% | 0.02% | -63.3% |
| Q4 2021 | $788,000 | +280.7% | 26,922 | +230.6% | 0.05% | +206.2% |
| Q3 2021 | $207,000 | -36.1% | 8,143 | +2.5% | 0.02% | -46.7% |
| Q1 2021 | $324,000 | -51.6% | 7,947 | -48.5% | 0.03% | -57.7% |
| Q4 2020 | $669,000 | +1.1% | 15,443 | +28.6% | 0.07% | +65.1% |
| Q3 2020 | $662,000 | -22.8% | 12,009 | -11.7% | 0.04% | -28.3% |
| Q2 2020 | $858,000 | +91.1% | 13,595 | +54.7% | 0.06% | +81.8% |
| Q1 2020 | $449,000 | -24.8% | 8,789 | -22.1% | 0.03% | -21.4% |
| Q1 2019 | $597,000 | -55.1% | 11,279 | -67.7% | 0.04% | -58.0% |
| Q3 2018 | $1,329,000 | +564.5% | 34,966 | +690.0% | 0.10% | +614.3% |
| Q2 2018 | $200,000 | -86.7% | 4,426 | -85.8% | 0.01% | -86.7% |
| Q1 2018 | $1,506,000 | +645.5% | 31,185 | +378.4% | 0.10% | +105.9% |
| Q3 2017 | $202,000 | – | 6,518 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |